Search company, investor...
Satsuma Pharmaceuticals company logo

Satsuma Pharmaceuticals

Founded Year



Acq - Pending | Acquired

Total Raised


About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals (NASDAQ: STSA) is a biopharmaceutical company. It develops, manufactures, and commercializes drug therapies for migraine. The company was founded in 2016 and is based in South San Francisco, California.

Headquarters Location

400 Oyster Point Boulevard Suite 221

South San Francisco, California, 94080,

United States


Missing: Satsuma Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Satsuma Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Satsuma Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Satsuma Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Satsuma Pharmaceuticals Patents

Satsuma Pharmaceuticals has filed 5 patents.

The 3 most popular patent topics include:

  • Antimigraine drugs
  • Piperazines
  • Piperidines
patents chart

Application Date

Grant Date


Related Topics




Prodrugs, Progestogens, Ketones, Androgens and anabolic steroids, Designer drugs


Application Date


Grant Date



Related Topics

Prodrugs, Progestogens, Ketones, Androgens and anabolic steroids, Designer drugs



Latest Satsuma Pharmaceuticals News

NDA for anti-migraine nasal powder to undergo FDA review

Jun 2, 2023

Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio The FDA has accepted for review a 505(b)(2) new drug application for STS101, a novel, investigational nasal powder for the acute treatment of migraine. The powder is a formulation of the anti-migraine drug dihydroergotamine (DHE) mesylate, which is administered with a proprietary nasal delivery device, according to a press release from its maker, Satsuma Pharmaceuticals. The FDA has accepted for review a 505(b)(2) new drug application for STS101, a novel, investigational nasal powder for the acute treatment of migraine. The treatment is intended to be a quicker and more convenient method of self-administration than current DHE liquid nasal sprays and injectables. The company’s NDA is backed by results from two clinical trials: a phase 1 comparative pharmacokinetic and safety trial completed in June 2021 and the ASCEND phase 3 long-term, open-label safety trial, during which 446 patients treated more than 9,000 migraine attacks with more than 10,500 doses of STS101 for up to 18 months, the release stated. Though not required by the FDA, the application also included results from the SUMMIT phase 3 trial, in which STS101 showed numerical but not statistical significance on primary endpoints of freedom from pain and most bothersome symptoms of migraine. Satsuma stated that the investigational therapeutic demonstrated “robust and sustained effects” on the endpoints up to 48 hours after dosing, as well as on “numerous secondary endpoints.” Satsuma’s president and CEO, John Kollins, said in the release that the acceptance is an “important milestone” toward “making STS101 available as an easy-to-use, effective, and safe and well-tolerated DHE treatment that can address the significant unmet clinical needs of many people with migraine.” Read more about

Satsuma Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Satsuma Pharmaceuticals founded?

    Satsuma Pharmaceuticals was founded in 2016.

  • Where is Satsuma Pharmaceuticals's headquarters?

    Satsuma Pharmaceuticals's headquarters is located at 400 Oyster Point Boulevard, South San Francisco.

  • What is Satsuma Pharmaceuticals's latest funding round?

    Satsuma Pharmaceuticals's latest funding round is Acq - Pending.

  • How much did Satsuma Pharmaceuticals raise?

    Satsuma Pharmaceuticals raised a total of $74M.

  • Who are the investors of Satsuma Pharmaceuticals?

    Investors of Satsuma Pharmaceuticals include Shin Nippon Biomedical Laboratories, RA Capital Management, TPG Biotech, Surveyor Capital, Eventide Asset Management and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.